Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. The company is headquartered in Acton, Massachusetts and currently employs 101 full-time employees. The firm provides testing services for the detection of drugs of abuse through the analysis of hair samples. Its testing methods utilize a patented technology that digests the hair and releases drugs trapped in the hair without destroying the drugs. The firm customizes its enzyme immunoassay (EIA) procedures to drug test hair samples. The company provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, phenylcyclohexyl piperidine (PCP), amphetamines (including ecstasy, eve, and Adderall), opiates (including heroin, hydrocodone, hydromorphone, oxycodone and codeine), synthetic cannabinoids (including K2, Spice, Blaze), benzodiazepines (Xanax, Valium, and Ativan), nicotine, Fentanyl, and alcohol. The firm markets its corporate drug testing services through its own sales force, distributors, and partners. The company markets its home drug testing service, PDT-90, through the Internet.
PMDI stock price ended at $1.64 on 星期四, after dropping 1.20%
On the latest trading day Jan 15, 2026, the stock price of PMDI fell by 1.20%, dropping from $1.64 to $1.64. During the session, the stock saw a volatility of 8.61%, with prices oscillating between a daily low of $1.51 and a high of $1.64. On the latest trading day, the trading volume for PMDI decreased by 27.1K shares, aligning with the declining prices, which may indicate weakening market confidence in the near term. In total, 1.5K shares were traded, with a market value of approximately $10.0M.